Zobrazeno 1 - 10
of 2 311
pro vyhledávání: ''
Autor:
David Malka, Cedric Lecaille, Anne-Laure Bignon, Nicolas Williet, Caroline Pétorin, Thomas Aparicio, Jérôme Desramé, Jean-Marc Phelip, Côme Lepage, Eric Francois, Yves Rinaldi, Anthony Turpin, Prodige Investigators, Karine Le Malicot, Laetitia Dahan, Jean-François Seitz, Christine Rebischung, Olivier Bouché, Jean-Baptiste Bachet
Publikováno v:
Journal of Clinical Oncology. 39:3242-3250
PURPOSE Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4—ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over
Autor:
Philip He, Robin Kate Kelley, Ho Yeong Lim, Takuji Okusaka, Thomas Yau, David Wai-Meng Tai, Ghassan K. Abou-Alfa, Masafumi Ikeda, Bruno Sangro, Yoon-Koo Kang, Silvia Damian, Johanna C. Bendell, Mitesh J. Borad, William P. Harris, Tae-You Kim, Shukui Qin, Alejandra Negro, Mallory Makowsky, Nathan Standifer, Masatoshi Kudo, Ann-Lii Cheng, Jordi Bruix, Antonio Gasbarrini, Wei Peng Yong
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 27
PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unre
Autor:
Vernon K. Sondak, Andrew Poklepovic, Nikhil I. Khushalani, Jason J. Luke, Sunil Babu, Sigrun Hallmeyer, Zeynep Eroglu, Mario R. Velasco, Emily F. Higgs, Bruce Brockstein, Daniel J Olson, Thomas Krausz, Madhuri Bajaj, Timothy Carll, Riyue Bao, Jose Lutzky, Theodore Karrison, Brian W. Labadie, Thomas F. Gajewski, Yuanyuan Zha
Publikováno v:
J Clin Oncol
PURPOSE Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and p
Autor:
Priya Kumthekar, Anita Fung, Nan Lin, Anna Cheng, Nuhad K. Ibrahim, Solmaz Sahebjam, Mark D. Pegram, Alan Nicholas, Whitney P. Kirschbrown
Publikováno v:
Journal of Clinical Oncology. 39:2667-2675
PURPOSE Effective therapies are needed for the treatment of patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) with brain metastases. A trastuzumab radioisotope has been shown to localize in brain me
Autor:
Lu Xu, Delvys Rodriguez-Abreu, Te Chun Hsia, Mehmet Ali Nahit Sendur, Perran Fulden Yumuk, A. Samkari, Irfan Cicin, Olivier Molinier, Bilal Piperdi, Keynote Investigators, Adrian Langleben, Dae Ho Lee, Balazs Medgyasszay, Francisco Orlandi, Michael Boyer, Ticiana A. Leal, Raffaele Califano, Gregory A. Otterson, Martin Reck, Keunchil Park, Nopadol Soparattanapaisarn
Publikováno v:
Journal of Clinical Oncology. 39:2327-2338
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It is not known whet
Autor:
Hiroji Iwata, Antonia Ridolfi, Christelle Levy, Yeon Hee Park, Ines Lorenzo, Fabrice Andre, Dejan Juric, Mario Campone, Tamar Safra, Hope S. Rugo, Norikazu Masuda, Frederic Forget, Juan Ignacio Delgado Mingorance, Ingrid A. Mayer, Sibylle Loibl, Pierfranco Conte, Jinhee Park, Eva Ciruelos, Xiaolei Zhou
Publikováno v:
Journal of Clinical Oncology. 39:2005-2015
PURPOSE In the phase III SOLAR-1 trial ( NCT02437318 ), the PI3Kα-selective inhibitor and degrader alpelisib significantly improved median progression-free survival when added to fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-k
Autor:
Christopher Sweeney, Eric Winquist, Darren R. Feldman, Ugo De Giorgi, Daniel Y.C. Heng, Silke Gillessen, Michal Chovanec, Jourik A. Gietema, Robert Huddart, Costantine Albany, Fay H. Cafferty, Peter Grimison, Aaron R. Hansen, Carsten Bokemeyer, Karim Fizazi, Jörg Beyer, Christian D. Fankhauser, Nicolas Sauvé, Alexey Tryakin, Torgrim Tandstad, Olof Ståhl, Helene F. S. Negaard, Ronald de Wit, Anja Lorch, Andrea Necchi, David J. Vaughn, Angelika Terbuch, Axel Heidenreich, Cora N. Sternberg, Marcus Hentrich, Xavier Garcia-del-Muro, Gedske Daugaard, Laurence Collette, Jonathan Shamash
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
J Clin Oncol
Gillessen, Silke; Sauvé, Nicolas; Collette, Laurence; Daugaard, Gedske; de Wit, Ronald; Albany, Costantine; Tryakin, Alexey; Fizazi, Karim; Stahl, Olof; Gietema, Jourik A; De Giorgi, Ugo; Cafferty, Fay H; Hansen, Aaron R; Tandstad, Torgrim; Huddart, Robert A; Necchi, Andrea; Sweeney, Christopher J; Garcia-Del-Muro, Xavier; Heng, Daniel Y C; Lorch, Anja; ... (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), pp. 1563-1574. 10.1200/JCO.20.03296
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), 1563-+. AMER SOC CLINICAL ONCOLOGY
Universidad de Barcelona
J Clin Oncol
Gillessen, Silke; Sauvé, Nicolas; Collette, Laurence; Daugaard, Gedske; de Wit, Ronald; Albany, Costantine; Tryakin, Alexey; Fizazi, Karim; Stahl, Olof; Gietema, Jourik A; De Giorgi, Ugo; Cafferty, Fay H; Hansen, Aaron R; Tandstad, Torgrim; Huddart, Robert A; Necchi, Andrea; Sweeney, Christopher J; Garcia-Del-Muro, Xavier; Heng, Daniel Y C; Lorch, Anja; ... (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), pp. 1563-1574. 10.1200/JCO.20.03296
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), 1563-+. AMER SOC CLINICAL ONCOLOGY
PURPOSE The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990. MATERIALS AND METHODS Da
Autor:
Zhihong Chi, Li Zhou, Bin Lian, Bixia Tang, Hong Yao, Jun Guo, Lu Si, Lili Mao, Chuanliang Cui, Xue Bai, Xuan Wang, Siming Li, Xieqiao Yan, Yan Kong, Xinan Sheng, Jie Dai
Publikováno v:
Journal of Clinical Oncology. 39:881-889
PURPOSE Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis. In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination with carboplatin plus paclitaxel (CP
Autor:
Hani Hassoun, Jacob P. Laubach, Jan S. Moreb, Sara Thuresson, Paula Rodriguez-Otero, Marcus Thuresson, Michele Cavo, Albert Oriol, Maria-Victoria Mateos, Joan Bladé, John W. Hiemenz, Adrian Alegre, Amitabha Mazumder, Horizon (Op ) Investigators, Kenneth C. Anderson, Omar Nadeem, Johan Harmenberg, Nicolaas A Bakker, Xavier Leleu, Alessandra Larocca, Christopher Maisel, Paul G. Richardson, Agne Paner, Anastasios Raptis, Cyrille Touzeau, Catriona Byrne
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Journal of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen
Autor:
Shengxiang Ren, Lunxu Liu, Shun Xu, Ke-Neng Chen, Weimin Mao, Xiaofei Li, Wen-Zhao Zhong, Rong Yin, Bu-Hai Wang, Jian Li, Qun Wang, Shidong Xu, Cheng Huang, Yi-Long Wu, Haitao Ma, Ping Yu, Songtao Xu, Hong-Hong Yan, Jin-Ji Yang, Qing Zhou, Chun Chen, Si-Yang Liu, Ying Cheng, Fan Yang, Lin Wu, Zhidong Liu, Xue-Ning Yang, Yucheng Wei, Yongyu Liu
Publikováno v:
Journal of Clinical Oncology. 39:713-722
PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079 ), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients wit